KR20080007642A - 프로테아좀 억제제와 함께 17-aag 또는 17-ag 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법 - Google Patents

프로테아좀 억제제와 함께 17-aag 또는 17-ag 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법 Download PDF

Info

Publication number
KR20080007642A
KR20080007642A KR1020077027765A KR20077027765A KR20080007642A KR 20080007642 A KR20080007642 A KR 20080007642A KR 1020077027765 A KR1020077027765 A KR 1020077027765A KR 20077027765 A KR20077027765 A KR 20077027765A KR 20080007642 A KR20080007642 A KR 20080007642A
Authority
KR
South Korea
Prior art keywords
aag
dose
prodrug
administered
max
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077027765A
Other languages
English (en)
Korean (ko)
Inventor
쥬니어 로버트 지 존슨
앨리슨 엘 한나
질리안 에프 크롭
이칭 쩌우
제이 마이클 쉐릴
Original Assignee
코산 바이오사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코산 바이오사이언시즈, 인코포레이티드 filed Critical 코산 바이오사이언시즈, 인코포레이티드
Publication of KR20080007642A publication Critical patent/KR20080007642A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077027765A 2005-04-29 2006-04-26 프로테아좀 억제제와 함께 17-aag 또는 17-ag 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법 Withdrawn KR20080007642A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US67655605P 2005-04-29 2005-04-29
US60/676,556 2005-04-29
US68623205P 2005-05-31 2005-05-31
US60/686,232 2005-05-31
US74919005P 2005-12-09 2005-12-09
US60/749,190 2005-12-09

Publications (1)

Publication Number Publication Date
KR20080007642A true KR20080007642A (ko) 2008-01-22

Family

ID=37308288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077027765A Withdrawn KR20080007642A (ko) 2005-04-29 2006-04-26 프로테아좀 억제제와 함께 17-aag 또는 17-ag 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법

Country Status (10)

Country Link
US (1) US20060252740A1 (cg-RX-API-DMAC7.html)
EP (1) EP1874297A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008539273A (cg-RX-API-DMAC7.html)
KR (1) KR20080007642A (cg-RX-API-DMAC7.html)
AU (1) AU2006242446A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0609861A2 (cg-RX-API-DMAC7.html)
CA (1) CA2604424A1 (cg-RX-API-DMAC7.html)
IL (1) IL186293A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007013499A (cg-RX-API-DMAC7.html)
WO (1) WO2006119032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
CA2604473A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either
DE102006026464A1 (de) * 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
TW200901960A (en) * 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009023846A2 (en) * 2007-08-15 2009-02-19 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
US8672869B2 (en) * 2007-10-30 2014-03-18 Bellco S.R.L. Kit, system and method of treating myeloma patients
GEP20156300B (en) * 2008-05-20 2015-06-25 Incuron Llc Inducing cell death by inhibiting adaptive heat shock response
SI2318419T2 (sl) 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
WO2010054381A2 (en) * 2008-11-10 2010-05-14 Mount Sinai School Of Medicine Of New York University Method of treating cancer with a combination of a proteasome inhibitor and salubrinal
AU2009347159B2 (en) * 2009-05-27 2015-09-03 Cephalon, Inc. Combination therapy for the treatment of multiple myeloma
UA121389C2 (uk) 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії
US20180172712A1 (en) * 2015-06-16 2018-06-21 Mayo Foundation For Medical Education And Research Methods and materials for assessing hydrogen peroxide accumulation in cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
CA2435146C (en) * 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
PT1373215E (pt) * 2001-03-30 2006-12-29 Uni S Of A R By The S D Of H H Derivado de geldanamicina e metodo de tratamento de cancro utilizando o mesmo
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US6887993B1 (en) * 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
SG171690A1 (en) * 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders

Also Published As

Publication number Publication date
IL186293A0 (en) 2008-01-20
AU2006242446A1 (en) 2006-11-09
EP1874297A1 (en) 2008-01-09
BRPI0609861A2 (pt) 2010-05-11
MX2007013499A (es) 2008-01-24
JP2008539273A (ja) 2008-11-13
WO2006119032A1 (en) 2006-11-09
US20060252740A1 (en) 2006-11-09
CA2604424A1 (en) 2006-11-09
EP1874297A4 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
US12161718B2 (en) Unit dose of a composition for treating cancer
US20060252740A1 (en) Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
US12403119B2 (en) Treating lymphomas
US8003105B2 (en) Method of treating cancer by co-administration of anticancer agents
CA3239730A1 (en) Stat3 degraders and uses thereof
US20090197852A9 (en) Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
EP0996461A1 (en) Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
JP2016515625A (ja) 増殖性疾患を治療するための併用療法
US7691392B2 (en) Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either
EP4353265A1 (en) Method for treating cancer through combination of cd47 inhibitor, immune checkpoint inhibitor, and standard therapy
KR20180006417A (ko) 카바지탁셀 및 암 치료에 대한 그의 용도
CN101166526A (zh) 用17-aag或17-ag或其前药与蛋白酶体抑制剂联合治疗多发性骨髓瘤的方法
WO2023230554A1 (en) Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
MX2008005467A (en) Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor
CN101528705A (zh) 17-aag或17-ag或两者之一的前药与her2抑制剂联用治疗乳腺癌的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071128

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid